Mylan Waives U.S. Distribution Rights for Kaletra Generic

Mylan announced that it has temporarily waived its exclusive U.S. distribution rights for its generic version of the HIV antiviral combo Kaletra (lopinavir/ritonavir), considered a potential treatment for COVID-19, in case further research shows the drug is effective in treating the novel coronavirus.

The waiving of exclusivity will allow other drugmakers to apply for FDA approval for their own generics and to manufacture them if they get the agency’s go-ahead.

The company said that it chose to suspend its exclusivity to provide a greater supply of the drug in case additional trials or evaluations show it has potential in treating the disease.